Compound ID | 1792

Update compound information

CMTX-101

Class: Antibody (monoclonal antibody [mAb])

Details of activity: Antivirulence approach, reduces biofilms
Combined with other compounds: Yes
Description: Humanized monoclonal antibody. Developed for moderate-to-severe pneumonia caused by Gram-positive or Gram-negative bacteria
Institute where first reported: Clarametyx Biosciences
Year first mentioned: 2020
Highest developmental phase: Phase 1/Phase 2 (NCT06159725)
Development status: Active (as of 2025)
External links:
Citations:
  • https://clarametyx.com/carb-x-awards-clarametyx-biosciences-3-89-million-in-additional-option-funding-to-accelerate-anti-biofilm-technology-for-life-threatening-bacterial-infections/
  • https://pubmed.ncbi.nlm.nih.gov/35052981/
  • https://clarametyx.com/our-platform/

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.